{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:53:06Z","timestamp":1781819586344,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81901667, Grant No. 82071841"],"award-info":[{"award-number":["Grant No. 81901667, Grant No. 82071841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peking Union Medical College Hospital Talent Cultivation Program(Category C, UBJ10806) and Beijing Key Clinical Specialty Program","award":["UBJ10806"],"award-info":[{"award-number":["UBJ10806"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>VEXAS syndrome is a severe autoinflammatory disease characterized by systemic inflammation, rheumatic manifestations, and hematologic abnormalities. Its clinical heterogeneity and overlap with other conditions complicate diagnosis. No case series have been reported from China. This study aimed to (1) describe the clinical features of Chinese patients with VEXAS syndrome and (2) propose screening recommendations to facilitate earlier identification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study at Peking Union Medical College Hospital, enrolling 57 male patients with unexplained systemic inflammation and hematologic abnormalities.\n                      <jats:italic>UBA1<\/jats:italic>\n                      gene sequencing was performed using bone marrow or peripheral blood samples. Clinical and laboratory data were extracted from electronic medical records. A screening model was developed using LASSO regression based on core features of confirmed cases and externally validated in two independent cohorts undergoing\n                      <jats:italic>UBA1<\/jats:italic>\n                      sequencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 57 suspected cases, 21 carried pathogenic\n                      <jats:italic>UBA1<\/jats:italic>\n                      variants. Compared with non-VEXAS patients, VEXAS patients more frequently showed older age at onset, skin lesions, chondritis, macrocytic anemia, and characteristic bone marrow vacuolization. Importantly, skin lesions were the initial presenting symptom in over half of VEXAS patients, whereas fever predominated in the non-VEXAS group. Rare manifestations included glomerulonephritis, acute cerebral infarction, and pulmonary arterial involvement. A novel\n                      <jats:italic>UBA1<\/jats:italic>\n                      variant (p.Thr318Met) was also identified. A screening model incorporating age at onset, skin lesions, chondritis, macrocytic anemia, and bone marrow vacuoles demonstrated good sensitivity and specificity in an external validation cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study is the first to characterize the clinical features of VEXAS syndrome in a Chinese population and to delineate its phenotypic spectrum. The proposed screening tool provides a practical aid for clinicians in identifying suspected cases and may facilitate improved diagnostic pathways and patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04380-9","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:20:55Z","timestamp":1781770855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and a screening tool for VEXAS syndrome: a case-control study from China"],"prefix":"10.1186","volume":"21","author":[{"given":"Menghui","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Mascaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Arostegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-0647","authenticated-orcid":false,"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"27","key":"4380_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease[J]. N Engl J Med. 2020;383(27):2628\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2026834.","journal-title":"N Engl J Med"},{"issue":"3","key":"4380_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-0043-1770958","volume":"10","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Dong X, Wang H. VEXAS Syndrome-Review[J]. Glob Med Genet. 2023;10(3):133\u201343. https:\/\/doi.org\/10.1055\/s-0043-1770958.","journal-title":"Glob Med Genet"},{"issue":"1","key":"4380_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.reumae.2023.12.004","volume":"20","author":"MP Loeza-Uribe","year":"2024","unstructured":"Loeza-Uribe MP, Hinojosa-Azaola A, S\u00e1nchez-Hern\u00e1ndez BE, et al. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment[J]. Reumatol Clin (Engl Ed). 2024;20(1):47\u201356. https:\/\/doi.org\/10.1016\/j.reumae.2023.12.004.","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"4","key":"4380_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.seminhematol.2021.10.005","volume":"58","author":"BA Patel","year":"2021","unstructured":"Patel BA, Ferrada MA, Grayson PC, et al. VEXAS syndrome: An inflammatory and hematologic disease[J]. Semin Hematol. 2021;58(4):201\u20133. https:\/\/doi.org\/10.1053\/j.seminhematol.2021.10.005.","journal-title":"Semin Hematol"},{"issue":"2","key":"4380_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.27156","volume":"99","author":"MJ Koster","year":"2024","unstructured":"Koster MJ, Lasho TL, Olteanu H, et al. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management[J]. Am J Hematol. 2024;99(2):284\u201399. https:\/\/doi.org\/10.1002\/ajh.27156.","journal-title":"Am J Hematol"},{"issue":"12","key":"4380_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard-2023-224460","volume":"82","author":"JM Mascaro","year":"2023","unstructured":"Mascaro JM, Rodriguez-Pinto I, Poza G, et al. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism[J]. Ann Rheum Dis. 2023;82(12):1594\u2013605. https:\/\/doi.org\/10.1136\/ard-2023-224460.","journal-title":"Ann Rheum Dis"},{"key":"4380_CR7","doi-asserted-by":"publisher","first-page":"800149","DOI":"10.3389\/fimmu.2021.800149","volume":"12","author":"F L\u00f6tscher","year":"2021","unstructured":"L\u00f6tscher F, Seitz L, Simeunovic H, et al. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease[J]. Front Immunol. 2021;12:800149. https:\/\/doi.org\/10.3389\/fimmu.2021.800149.","journal-title":"Front Immunol"},{"key":"4380_CR8","doi-asserted-by":"publisher","unstructured":"Rasch MNB, Szabados F, Jensen JMB, et al. Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers[J]. RMD Open. 2022;8(2). https:\/\/doi.org\/10.1136\/rmdopen-2022-002492.","DOI":"10.1136\/rmdopen-2022-002492"},{"issue":"7","key":"4380_CR9","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/s2665-9913(25)00034-7","volume":"7","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim A, Trikha R, Phyu Htut EE, et al. Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study[J]. Lancet Rheumatol. 2025;7(7):e472\u201384. https:\/\/doi.org\/10.1016\/s2665-9913(25)00034-7.","journal-title":"Lancet Rheumatol"},{"key":"4380_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20157","author":"E Diral","year":"2025","unstructured":"Diral E, Campochiaro C, Furnari G, et al. Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort[J]. Br J Haematol. 2025. https:\/\/doi.org\/10.1111\/bjh.20157.","journal-title":"Br J Haematol"},{"issue":"8","key":"4380_CR11","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1093\/rheumatology\/kead627","volume":"63","author":"J Rogez","year":"2024","unstructured":"Rogez J, Ravaiau C, Lacombe V. Comment on: Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome[J]. Rheumatology (Oxford). 2024;63(8):e231\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/kead627.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4380_CR12","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/s2352-3026(23)00375-7","volume":"11","author":"V Lacombe","year":"2024","unstructured":"Lacombe V, Hadjadj J, Georgin-Lavialle S, et al. Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond[J]. Lancet Haematol. 2024;11(2):e160\u20137. https:\/\/doi.org\/10.1016\/s2352-3026(23)00375-7.","journal-title":"Lancet Haematol"},{"issue":"2","key":"4380_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/1744666x.2023.2157262","volume":"19","author":"A Al-Hakim","year":"2023","unstructured":"Al-Hakim A, Savic S. An update on VEXAS syndrome[J]. Expert Rev Clin Immunol. 2023;19(2):203\u201315. https:\/\/doi.org\/10.1080\/1744666x.2023.2157262.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"4380_CR14","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1093\/rheumatology\/kead506","volume":"63","author":"BE S\u00e1nchez-Hern\u00e1ndez","year":"2024","unstructured":"S\u00e1nchez-Hern\u00e1ndez BE, Calder\u00f3n-Espinoza I, Mart\u00edn-Nares E. Challenging the paradigm: a case of early-onset VEXAS syndrome[J]. Rheumatology (Oxford). 2024;63(3):e99\u2013100. https:\/\/doi.org\/10.1093\/rheumatology\/kead506.","journal-title":"Rheumatology (Oxford)"},{"key":"4380_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae465","author":"K Kalantari","year":"2024","unstructured":"Kalantari K, Sullivan MM, Hernandez LPH, et al. Acute kidney injury, an underrecognized feature of VEXAS syndrome[J]. Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae465.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4380_CR16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.kint.2022.03.012","volume":"101","author":"C Ronsin","year":"2022","unstructured":"Ronsin C, Benard L, Mourtada A, et al. Acute tubulointerstitial nephritis revealing VEXAS syndrome[J]. Kidney Int. 2022;101(6):1295\u20137. https:\/\/doi.org\/10.1016\/j.kint.2022.03.012.","journal-title":"Kidney Int"},{"issue":"12","key":"4380_CR17","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1182\/blood.2024028133","volume":"146","author":"V Jachiet","year":"2025","unstructured":"Jachiet V, Kosmider O, Beydon M, et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX[J]. Blood. 2025;146(12):1450\u201361. https:\/\/doi.org\/10.1182\/blood.2024028133.","journal-title":"Blood"},{"issue":"3","key":"4380_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients[J]. Br J Dermatol. 2022;186(3):564\u201374. https:\/\/doi.org\/10.1111\/bjd.20805.","journal-title":"Br J Dermatol"},{"issue":"8","key":"4380_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","volume":"160","author":"IJ Tan","year":"2024","unstructured":"Tan IJ, Ferrada MA, Ahmad S, et al. Skin Manifestations of VEXAS Syndrome and Associated Genotypes[J]. JAMA Dermatol. 2024;160(8):822\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1657.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"4380_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12185-024-03799-9","volume":"122","author":"H Nakajima","year":"2025","unstructured":"Nakajima H, Kunimoto H. VEXAS syndrome[J]. Int J Hematol. 2025;122(3):341\u201350. https:\/\/doi.org\/10.1007\/s12185-024-03799-9.","journal-title":"Int J Hematol"},{"issue":"13","key":"4380_CR21","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis[J]. Blood. 2022;140(13):1496\u2013506. https:\/\/doi.org\/10.1182\/blood.2022016985.","journal-title":"Blood"},{"key":"4380_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/art.43287","author":"AM Mekinian","year":"2025","unstructured":"Mekinian AM, Georgin-Lavaille S, Ferrada MA, et al. American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel[J]. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43287.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"4380_CR23","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1093\/rheumatology\/kead425","volume":"63","author":"A Maeda","year":"2024","unstructured":"Maeda A, Tsuchida N, Uchiyama Y, et al. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome[J]. Rheumatology (Oxford). 2024;63(8):2056\u201364. https:\/\/doi.org\/10.1093\/rheumatology\/kead425.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"4380_CR24","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1093\/rheumatology\/kead626","volume":"63","author":"N Tsuchida","year":"2024","unstructured":"Tsuchida N, Uchiyama Y, Maeda A, et al. Comment on: Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome: reply[J]. Rheumatology (Oxford). 2024;63(8):e229\u201330. https:\/\/doi.org\/10.1093\/rheumatology\/kead626.","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"4380_CR25","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood.2023023593","volume":"143","author":"LE Hong","year":"2024","unstructured":"Hong LE, Wechalekar MD, Kutyna M, et al. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation[J]. Blood. 2024;143(18):1873\u20137. https:\/\/doi.org\/10.1182\/blood.2023023593.","journal-title":"Blood"},{"key":"4380_CR26","doi-asserted-by":"crossref","unstructured":"Salama N, Lynch O, Quarato ER, et al. Isocitrate dehydrogenase 2 mutation drives bone marrow macrophage dysfunction without a complete block in hematopoietic differentiation. Am Soc Hematol Washington, DC; 2022.","DOI":"10.1182\/blood-2022-168015"},{"issue":"33","key":"4380_CR27","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.18632\/oncotarget.26863","volume":"10","author":"CC Poon","year":"2019","unstructured":"Poon CC, Gordon PMK, Liu K, et al. Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma[J]. Oncotarget. 2019;10(33):3129\u201343. https:\/\/doi.org\/10.18632\/oncotarget.26863.","journal-title":"Oncotarget"},{"key":"4380_CR28","doi-asserted-by":"crossref","unstructured":"Desai P, Sugita M, Heise R, et al. Association of inflammatory cytokines with clonal hematopoiesis and progression to acute myeloid leukemia. Am Soc Hematol Washington, DC; 2022.","DOI":"10.1182\/blood-2022-166825"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04380-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:02:35Z","timestamp":1781816555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4380"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04380-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Peking Union Medical College Hospital (I-25PJ1435). The requirement for written informed consent was waived due to the retrospective nature of the study, minimal risk to participants, and the fact that some patients were deceased or lost to follow-up. No identifiable personal information was disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}